AIDS Trial Group Presents Results from Phase 1 of ModeX Trispecific Antibody
MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023. Business highlights...
MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2023 after the close of the...
MIAMI, Jan. 09, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (the œCompany) today announced the closing of its previously announced private offering of $230.0 million aggregate...
MIAMI, Jan. 08, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 42nd Annual J.P. Morgan Healthcare Conference, being held...
MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (the Company) today announced that it is commencing a private offering of $200.0 million aggregate principal amount of its...
MIAMI, Nov. 06, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended September 30, 2023. Business...
New Clinical Data on OPKO Health™s RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023
OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023
MIAMI, Oct. 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) will present late-breaking clinical data on RAYALDEE® extended-release calcifediol (ERC) at the American Society of...